Best Supplier of Gamithromycin CAS NO (145435-72-9) In Bulk

Here's an extensive description for Gamithromycin (145435-72-9):

1. Introduction to Gamithromycin (145435-72-9) Gamithromycin is a semi-synthetic macrolide antibiotic belonging to the subclass of azalides. It is primarily used in veterinary medicine for the treatment of respiratory and other bacterial infections in livestock, particularly in cattle and swine. Gamithromycin exhibits potent antibacterial activity against a broad spectrum of Gram-positive and Gram-negative bacteria, making it a valuable tool in veterinary practice for the management of infectious diseases.

2. Chemical Structure and Molecular Composition The molecular formula of gamithromycin is C40H76N2O12, representing a complex macrocyclic lactone ring structure with a nitrogen-containing side chain. Its chemical structure is derived from erythromycin through modifications that enhance its pharmacological properties, including improved stability, bioavailability, and efficacy against resistant bacterial strains. The molecular weight of gamithromycin is approximately 777.06 g/mol.

3. Mechanism of Action Gamithromycin exerts its antibacterial effects by binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and disrupting bacterial growth and replication. This mechanism is similar to other macrolide antibiotics, but gamithromycin's unique chemical structure confers enhanced potency and prolonged duration of action, allowing for less frequent dosing regimens in veterinary medicine.

4. Veterinary Applications Gamithromycin is approved for use in veterinary medicine for the treatment and control of respiratory tract infections, including bovine respiratory disease (BRD) and swine respiratory disease (SRD), caused by susceptible bacterial pathogens. It is administered parenterally, either via intramuscular or subcutaneous injection, to achieve therapeutic concentrations in target tissues and body fluids, such as lung tissue and bronchial secretions.

5. Spectrum of Activity Gamithromycin exhibits a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria commonly implicated in respiratory infections in livestock. This includes pathogens such as Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, Mycoplasma spp., and Actinobacillus pleuropneumoniae. Its potent activity and extended duration of action contribute to effective control and treatment of bacterial infections in veterinary practice.

6. Pharmacokinetics and Metabolism Following parenteral administration, gamithromycin is rapidly absorbed and distributed to various tissues and body fluids, achieving therapeutic concentrations at the site of infection. It undergoes hepatic metabolism, primarily by cytochrome P450 enzymes, to form inactive metabolites that are excreted predominantly via biliary and fecal routes. The pharmacokinetic profile of gamithromycin allows for convenient dosing intervals and sustained antibacterial activity in treated animals.

7. Safety and Adverse Effects Gamithromycin is generally well tolerated in livestock when administered at recommended doses. However, adverse effects such as local injection site reactions, transient gastrointestinal disturbances, or hypersensitivity reactions may occur in some animals. It is important to follow proper dosing protocols and monitor animals for any signs of adverse reactions during and after treatment with gamithromycin.

8. Resistance and Antimicrobial Stewardship As with any antibiotic, the emergence of antimicrobial resistance is a concern in veterinary medicine. Prudent use of gamithromycin and other antibiotics, in accordance with established guidelines and principles of antimicrobial stewardship, is essential to minimize the development and spread of resistant bacterial strains. Regular surveillance of bacterial susceptibility patterns and judicious use of antibiotics can help preserve the efficacy of gamithromycin for future generations.

9. Regulatory Status and Availability Gamithromycin is approved for veterinary use in several countries worldwide, including the United States, European Union, Canada, and others. It is available in various formulations, including injectable solutions and suspensions, for ease of administration to livestock species. Veterinary practitioners should adhere to local regulatory requirements and label instructions when prescribing and dispensing gamithromycin-containing products.

10. Research and Future Perspectives Ongoing research efforts focus on optimizing the pharmacological properties, dosage regimens, and treatment protocols for gamithromycin in veterinary medicine. Additionally, studies are underway to evaluate its efficacy in the management of emerging bacterial pathogens and respiratory infections in livestock populations. Collaborative initiatives between researchers, veterinarians, and industry stakeholders are essential to address current challenges and advance the field of veterinary antimicrobial therapy.

In conclusion, gamithromycin represents a valuable tool in veterinary medicine for the treatment and control of respiratory and other bacterial infections in livestock. Its potent antibacterial activity, broad spectrum of activity, and favorable pharmacokinetic profile make it a preferred choice for veterinary practitioners seeking effective antimicrobial therapy. However, responsible use and antimicrobial stewardship are crucial to preserve the efficacy of gamithromycin and other antibiotics for the long-term health and welfare of animals.